Skip to main content

Share story

Products

Coherent reports 56% pro forma revenue growth in fiscal first quarter

Coherent reports 56% pro forma revenue growth in fiscal first quarter Image: Primary
Coherent reported a 56% year-over-year increase in pro forma revenue for its fiscal first quarter of 2027, with non-GAAP earnings per share rising 80%. The company supplies optical components used in AI data centers. James Robert Anderson said established product lines drove strong growth, while newer growth areas were only beginning to ramp. The reported comparisons use pro forma revenue and non-GAAP earnings, rather than GAAP measures.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from 24/7 Wall St. and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Infrastructure
Infrastructure

Google plans $15B Malaysian data center and cloud investment

Google plans to spend $15B in Malaysia during 2027 and 2028 on data centers, cloud operations, water supplies, power generation and training, The Next Web reports. Alphabet chief investment officer Ruth Porat announced the plan at an event in Kuala Lumpur.

Capital AI
Capital AI

Pliant raises $80M for expansion and AI payment workflows

Pliant raised an $80M Series C led by Seaya Nova and Speedinvest, the Berlin fintech said Wednesday. The funding will support expansion in the US and Canada, entry into additional markets and its AI roadmap.

Robotics Capital
Robotics Capital

Aformic raises $6.95M to expand industrial robotics

Aformic raised a $6.95M seed round led by Veteran Ventures Capital, the industrial robotics company said Wednesday. It will use the funding for engineers, sales staff, its Qursor software and new robots, including machines intended to help build and maintain AI data centres.

AI Capital
AI Capital

Isomorphic Labs seeks roughly $5 billion in funding talks

Alphabet's Isomorphic Labs is in talks to raise roughly $5 billion to support its use of artificial intelligence for drug discovery, Bloomberg reported, citing people familiar with the matter. The financing remains under discussion rather than a completed fundraising.